Walgreens Boots Alliance, Inc.

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Nov. 10, 2014, 7:02 AM
    • Walgreen (NYSE:WAG) plans to sell bonds in Europe to help finance its purchase of Alliance Boots, according to Bloomberg.
    • It's a move viewed as logical by analysts with the Walgreen Boots Alliance unit bringing in European revenue.
    • The sale is expected to include £600M ($954M) of notes split between 6-year and 10-year maturities and up to €750M euros ($937M) of 12-year bonds.
    | Nov. 10, 2014, 7:02 AM
  • Oct. 28, 2014, 11:32 AM
    • Redbook notes the timing of Halloween on a Friday is giving a boost to merchandise sales related to the holiday as more consumers prep for parties and celebrations.
    • Both Redbook and ICSC's weekly read on retail store sales showed year-over-year improvement with Halloween sales a factor.
    • Stores have also been extending their hours to draw in more shoppers.
    • Looking for a Halloween boost: DLTR, DG, FDO, KR, SVU, SWY, WMT, TGT, HSY, KRFT, CVS, RAD, WAG, MDLZ.
    | Oct. 28, 2014, 11:32 AM | 5 Comments
  • Oct. 21, 2014, 3:44 PM
    • CtW Investment Group calls on Walgreen (WAG +2.5%) to investigate allegations made by a former CFO in a defamation lawsuit.
    • The activist investment firm wants a new independent financial adviser to be retained.
    • CtW is already on record as opposing Walgreen's merger with Alliance Boots.
    | Oct. 21, 2014, 3:44 PM | 6 Comments
  • Oct. 20, 2014, 10:47 AM
    • CVS Health (CVS +1%) plans to charge some customers a $15 co-payment fee for any prescriptions filled at a pharmacy which also sells tobacco products.
    • The initiative could boost sales at CVS drugstores as consumers switch to the cheaper option, according to industry insiders.
    • Large drugstore chains such as Walgreen (WAG +0.1%) and Rite Aid (RAD +0.6%), along with small independent pharmacies, are expected to cry foul over the CVS strategy.
    | Oct. 20, 2014, 10:47 AM | 32 Comments
  • Oct. 20, 2014, 10:31 AM
    • There's some dysfunction at Walgreen (WAG +0.3%) as a testy lawsuit against the company filed by former CFO Wade Miquelon accuses the CEO and a board member of defaming him in meetings with investors.
    • Miquelon disputes the contention that he was responsible for a faulty forecast on generic drug prices which ended cutting into a profit target by $1.1B.
    • Some of the employees that worked with Miquelon in the finance group are still at the company.
    | Oct. 20, 2014, 10:31 AM | 1 Comment
  • Oct. 14, 2014, 3:31 PM
    • Global growth, foreign-exchange, oil, and small caps are the subject of every client inquiry, says David Kostin. His team's recommendation: Buy "American exceptionalism."
    • In Kostin's view, U.S. economy and corporate fundamentals are still strong, with economic growth expected by Goldman economists to be 3.2% next year, the fastest expansion since 2005. Europe is expected to grow just 1%.
    • What his team likes are those stocks of companies which have a high proportion of domestic sales, plus sectors like Consumer Staples (XLP -0.1%) and Discretionary (XLY +0.7%) which stand to benefit from lower oil prices (plunging again today).
    • As for small caps (IWM +0.9%), Kostin is wary, noting downward earnings revisions have boosted small cap P/E ratios even as prices have declined.
    • The list of S&P 500 names capturing two or more of Kostin's themes: GT, GM, PCLN, AMZN, CMCSA, LOW, DG, TSN, ADM, CVS, AVP, WAG, PXD, HAL, JPM, BAC, SCHW, PNC, MS, C, GNW, LNC, MET, THC, AET, UNH, ESRX, HUM, WLP, BIIB, GILD, DAL, CMI, FLR, CRM, JBL, MA, FB, MU, FSLR, VMC, MON, T.
    | Oct. 14, 2014, 3:31 PM | 26 Comments
  • Oct. 9, 2014, 4:00 PM
    • It's unlikely that the strong dollar will impact Q3 earnings as much as people think, Diane Garnick, CEO of global asset management firm Clear Alternatives says. But it will impact Q4 earnings. We're likely to see companies meet or exceed earnings in Q3, but give downward forecasts for Q4, she says.
    • Companies with bigger international exposure, like Wal-Mart (NYSE:WMT) will lower their estimates more. The same is true for sectors dominated by companies with global exposure like financials (NYSEARCA:XLF).
    • Conversely, companies like Walgreen (NYSE:WAG) who are almost all U.S. dollar based will be less impacted by a stronger dollar. Also relevant for ETFs like XLP and XLU.
    • Link: Reuters Insider
    | Oct. 9, 2014, 4:00 PM
  • Oct. 8, 2014, 4:50 PM
    • Walgreen  (NYSE:WAG) declares $0.3375/share quarterly dividend, in line with previous.
    • Forward yield 2.20%
    • Payable Dec. 12; for shareholders of record Nov. 17; ex-div Nov. 13.
    | Oct. 8, 2014, 4:50 PM
  • Oct. 3, 2014, 8:14 AM
    • Walgreen (NYSE:WAG) reports front-end sales rose 2.2% in September, led by a 4.4% increase in the average basket size of customers.
    • Total sales +9.4% to $6.48B.
    • Comparable-store prescriptions filled +6.6%.
    • Flu shots +10.5% to 2.1M.
    • Store count +5 (net).
    | Oct. 3, 2014, 8:14 AM
  • Oct. 1, 2014, 9:01 AM
    • Express Scripts (NASDAQ:ESRX) will feature Walgreens (NYSE:WAG) as the preferred retail pharmacy in its two national Medicare Prescription Drug Plans. Medicare beneficiaries enrolled in the Express Scripts Value or Choice Plans will either pay $0 (Value) or $1 (Choice) copayments for Tier 1 generic medications when using one of the more than 27,000 pharmacies in the plans' preferred retail network (8,200 Walgreens pharmacies and 18,500 community pharmacies).
    • Specific financial aspects of the collaboration, if any, are undisclosed.
    | Oct. 1, 2014, 9:01 AM
  • Sep. 30, 2014, 2:51 PM
    • Walgreen (WAG -0.2%) continues to feel an impact from its generic pricing miscalculation that led to the dismissal of several high-level execs.
    • During the firm's earnings call, management highlighted how lower drug reimbursement rates could continue to crimp profits as the company reels in less than a more favorable contract would have brought in.
    • Earnings call webcast
    | Sep. 30, 2014, 2:51 PM
  • Sep. 30, 2014, 7:54 AM
    • Walgreen (NYSE:WAG): FQ4 EPS of $0.74 in-line.
    • Revenue of $19.1B (+6.5% Y/Y) beats by $80M.
    • Shares +2% PM.
    | Sep. 30, 2014, 7:54 AM
  • Sep. 30, 2014, 7:38 AM
    • Walgreen (NYSE:WAG) reports comparable-store sales increased 5.4% in FQ4.
    • Front-end comparable stores sales rose 1.3% during the quarter, while the prescription comp was up 7.8%.
    • Store traffic fell 2.2%.
    • Customer basket size +3.5%.
    • Gross profit rate -90 bps to 28.0%.
    • The company says synergies churned up by the merger with with Alliance Boots will reach $491M this fiscal year and $650M in FY15.
    • WAG +1.5% premarket
    | Sep. 30, 2014, 7:38 AM | 1 Comment
  • Sep. 29, 2014, 5:30 PM
    | Sep. 29, 2014, 5:30 PM
  • Sep. 24, 2014, 1:45 AM
    • Walgreen (NYSE:WAG) is considering the sale of just over 50% of its infusion services business, in a deal that could value the unit at around $1.5B.
    • The division offers infusion services at home and at care centers across the U.S. Infusion therapies are used for medical conditions such as bleeding disorders and serious infections.
    • BofA has been hired by Walgreen for the sale, which has already attracted interest from several private equity firms.
    | Sep. 24, 2014, 1:45 AM
  • Sep. 23, 2014, 1:24 PM
    • Walgreens (WAG +1.4%) will report fiscal Q4 earnings on Tuesday, September 30 at 7:30 am ET followed by a conference call with management.
    • Consensus views for fiscal Q4 and fiscal 2014 are EPS of $0.74 on revenues of $19B and EPS of $3.29 on revenues of $76.3B, respectively.
    | Sep. 23, 2014, 1:24 PM
Company Description
Walgreens Boots Alliance Inc operates drug-stores chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug-stores, as well as mail, and by telephone and online.
Sector: Services
Industry: Drug Stores
Country: United States